63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200057058 | 2022-07-01 | 2022-02-27 | A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With Rituximab In The Treatment Of Steroid-Ineffective Primary Immune Thrombocytopenia | A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With Rituximab In The Treatment Of Steroid-Ineffective Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | Therapy Group:Zanubrutinib (80 mg, 2 times/day, for a total of 12 weeks) combined with Rituximab (375 mg/m2, 1 intravenous infusion) regimen; | The Second Affiliated Hospital of Kunming Medical University | NULL | Pending | 18 | 70 | Both | Therapy Group:23; | Phase 1 | China |
| 2 | NCT05369377 (ClinicalTrials.gov) | June 1, 2022 | 6/5/2022 | Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia | Zanubrutinib and Eltrombopag as Second-line Treatment for Patients With Immune Thrombocytopenia: a Multicentre, Open-label,Randomised, Controlled, Phase 2 Trial | Immune Thrombocytopenia | Drug: Zanubrutinib;Drug: Eltrombopag | Peking University People's Hospital | Beijing Hospital;The Sixth Medical Center of PLA General Hospital;Beijing Aerospace General Hospital;Qilu Hospital of Shandong University;Beijing Tongren Hospital | Not yet recruiting | 18 Years | 70 Years | All | 150 | Phase 2 | China |